Claims for Patent: 10,300,139

Summary for Patent: 10,300,139

Title:	Selectively altering microbiota for immune modulation
Abstract:	The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
Inventor(s):	Clube; Jasper (London, GB)
Assignee:	SNIPR TECHNOLOGIES LIMITED (London, GB)
Application Number:	16/041,595
Patent Claims:	1. A method for modulating a therapy of a disease or condition in a human or animal patient, the method comprising increasing the relative proportion of a sub-population of gram positive bacteria in a microbiota of the patient, wherein the therapy comprises administration of an effective amount of an immune checkpoint inhibitor to the patient, and wherein the immune checkpoint inhibitor is a Programmed Cell Death Protein 1 (PD-1) inhibitor or a Programmed Death-Ligand 1 (PD-L1) inhibitor, and wherein the method comprises selectively killing or reducing growth of a bacterial or archael sub-population in the microbiota using a guided nuclease. 2. The method of claim 1, wherein the immune checkpoint inhibitor is an antibody. 3. The method of claim 1, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody. 4. The method of claim 3, wherein the immune checkpoint inhibitor is nivolumab, pembrolizumab, or pidilizumab, durvalumab, or atezolizumab. 5. The method of claim 1, wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody. 6. The method of claim 5, wherein the immune checkpoint inhibitor is durvalumab or atezolizumab. 7. The method of claim 1, wherein the microbiota is gut microbiota. 8. The method of claim 1, wherein the gram positive bacteria comprise Ruminococcus. 9. The method of claim 1, wherein the gram positive bacteria comprise Clostridium. 10. The method of claim 1, wherein the method comprises administering a bacterial transplant to the patient. 11. The method of claim 10, wherein the bacterial transplant comprises Ruminococcus. 12. The method of claim 10, wherein the bacterial transplant comprises Clostridium. 13. The method of claim 1, wherein the guided nuclease is a Cas, transcription activator-like effector nuclease (TALEN), meganuclease or zinc finger nuclease. 14. The method of claim 13, wherein the microbiota comprises a mixed population of human gut microbiota bacteria of different species, and wherein the selective killing comprises selectively killing cells of one or more of the different species and sparing cells of the other species. 15. The method of claim 1, wherein the sub-population of gram positive bacteria comprise Ruminococcus. 16. The method of claim 14, wherein the sub-population of gram positive bacteria comprise Clostridium. 17. The method of claim 1, wherein the disease is cancer. 18. The method of claim 17, wherein the cancer is melanoma, renal cell carcinoma, lung cancer, bladder carcinoma, central nervous system (CNS) tumor or Hodgkin's disease.

Details for Patent 10,300,139

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014		2036-06-05
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015		2036-06-05
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014		2036-06-05
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	10/04/2017		2036-06-05
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	08/27/2021		2036-06-05
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034	05/18/2016		2036-06-05
Genentech, Inc.	TECENTRIQ	atezolizumab	Injection	761034	03/08/2019		2036-06-05